236 related articles for article (PubMed ID: 9117804)
1. Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF; Reitz J
Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804
[TBL] [Abstract][Full Text] [Related]
2. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in the treatment of metastatic pancreatic cancer.
Hilbig A; Oettle H
Expert Rev Anticancer Ther; 2008 Apr; 8(4):511-23. PubMed ID: 18402518
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
5. Preclinical, pharmacologic, and phase I studies of gemcitabine.
Storniolo AM; Allerheiligen SR; Pearce HL
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-2-S7-7. PubMed ID: 9194473
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
8. [An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Fukuoka M; Noda K; Hasegawa K; Nakajima H; Furuse K; Hirabayashi K; Hasegawa K; Ogura T; Niitani H; Taguchi T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1813-24. PubMed ID: 8937492
[TBL] [Abstract][Full Text] [Related]
9. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Brand R; Capadano M; Tempero M
Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
[TBL] [Abstract][Full Text] [Related]
12. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
Veltkamp SA; Beijnen JH; Schellens JH
Oncologist; 2008 Mar; 13(3):261-76. PubMed ID: 18378536
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
[TBL] [Abstract][Full Text] [Related]
14. Role of gemcitabine in cancer therapy.
Toschi L; Finocchiaro G; Bartolini S; Gioia V; Cappuzzo F
Future Oncol; 2005 Feb; 1(1):7-17. PubMed ID: 16555971
[TBL] [Abstract][Full Text] [Related]
15. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
[TBL] [Abstract][Full Text] [Related]
16. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
17. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
18. [New antitumor antimetabolites--gemcitabine and DMDC].
Matsui K; Fukuoka M
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2127-32. PubMed ID: 1332622
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of gemcitabine using a once every 2 weeks schedule.
Vermorken JB; Guastalla JP; Hatty SR; Seitz DE; Tanis B; McDaniels C; Clavel MD
Br J Cancer; 1997; 76(11):1489-93. PubMed ID: 9400947
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine: a pharmacologic and clinical overview.
Barton-Burke M
Cancer Nurs; 1999 Apr; 22(2):176-83. PubMed ID: 10217035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]